Drug Information

Drug General Information
Drug ID
D05NEC
Former ID
DIB019232
Drug Name
compound 13r
Drug Type
Small molecular drug
Indication Discovery agent Investigative [532338]
Structure
Download
2D MOL
Formula
C26H24N6
InChI
InChI=1S/C26H24N6/c1-30-12-14-31(15-13-30)21-8-6-19(7-9-21)20-16-28-26-24(17-29-32(26)18-20)22-10-11-27-25-5-3-2-4-23(22)25/h2-11,16-18H,12-15H2,1H3
InChIKey
XBGWAKUQSRNWMA-UHFFFAOYSA-N
PubChem Compound ID
60182364
PubChem Substance ID
163720819, 174521930, 175447067, 249565824
Target and Pathway
Target(s) TGF-beta receptor type I Target Info Inhibitor [532338]
activin A receptor, type I Target Info Inhibitor [532338]
Bone morphogenetic protein receptor Target Info Inhibitor [532338]
Activin receptor-like kinase-1 Target Info Inhibitor [532338]
activin A receptor, type IB Target Info Inhibitor [532338]
KEGG Pathway MAPK signaling pathway
Cytokine-cytokine receptor interaction
FoxO signaling pathway
Endocytosis
TGF-beta signaling pathway
Osteoclast differentiation
Hippo signaling pathway
Adherens junction
Chagas disease (American trypanosomiasis)
Hepatitis B
HTLV-I infection
Pathways in cancer
Colorectal cancer
Pancreatic cancer
Chronic myeloid leukemiahsa04060:Cytokine-cytokine receptor interaction
Signaling pathways regulating pluripotency of stem cells
PANTHER Pathway TGF-beta signaling pathwayP00052:TGF-beta signaling pathway
Pathway Interaction Database Glypican 1 network
ALK1 signaling events
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
TGF-beta receptor signalingalk1_2pathway:ALK1 pathway
Reactome TGF-beta receptor signaling activates SMADs
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
SMAD2/3 Phosphorylation Motif Mutants in Cancer
SMAD2/3 MH2 Domain Mutants in Cancer
TGFBR2 Kinase Domain Mutants in Cancer
TGFBR1 KD Mutants in Cancer
TGFBR1 LBD Mutants in Cancer
WikiPathways TGF Beta Signaling Pathway
p38 MAPK Signaling Pathway
MAPK Signaling Pathway
TGF beta Signaling Pathway
Extracellular vesicle-mediated signaling in recipient cells
Cardiac Hypertrophic Response
Signaling by TGF-beta Receptor Complex
Integrated Pancreatic Cancer Pathway
Integrated Breast Cancer PathwayWP474:Endochondral Ossification
Ectoderm Differentiation
Mesodermal Commitment Pathway
Endoderm Differentiation
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Hair Follicle Development: Induction (Part 1 of 3)
Signaling by BMP
Integrated Breast Cancer Pathway
Heart Development
BMP Signalling and Regulation
References
Ref 532338Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
Ref 532338Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.